Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...949596979899100101102103104...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, PD(L)-1 Biomarker, IO Biomarker:  An update: emerging drugs to treat squamous cell carcinomas of the head and neck. (Pubmed Central) -  Oct 16, 2019   
    Introduction: Subsequent to the 2006 FDA approval of cetuximab, a variety of molecular targeting agents have been evaluated in head and neck squamous cell carcinoma (HNSCC)...Expert opinion: In recent years, there has been a major shift towards immunotherapy-based approaches for the treatment of HNSCC, leading to significant improvements in outcomes for a subset of patients. Leveraging the increased understanding of the genetic alterations that characterize individual HNSCC tumors will facilitate precision medicine approaches using targeted agents, immunotherapies, as well as standard chemotherapy and radiation.
  • ||||||||||  tacrolimus / Generic Mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Utility of Donor-Derived Cell-Free DNA for Detecting Allograft Rejection with PD-L1 Checkpoint Inhibitor Use (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4702;    
    His immunosuppression regimen included tacrolimus 2mg bid, mycophenolate 500mg bid and prednisone 5mg daily...He underwent radiation therapy followed by chemotherapy with Cetuximab...PD-L1 inhibitor, Pembrolizumab, was initiated in Nov 2017 with serial dd-cfDNA monitoring (weekly x 8 weeks, followed by monthly)...Future investigations into sequencing the dd-cfDNA will help determine whether it is of tumor vs allograft origin. Fig 1 Fig 2
  • ||||||||||  Contrary to Expectation: Preserved Renal Function After Using PD-1 Inhibitor Cemiplimab-rwlc in a Kidney Transplant Recipient (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4687;    
    He received Thymoglobulin induction and maintenance immunosuppression with Tacrolimus, MMF and Prednisone...Treatment included Mohs procedure, chemotherapy (paclitaxel/carboplatin/cetuximab) for 4 cycles and radiation for 5 months...Subsequently, he was switched from intratumoral 5FU to intratumoral IL2 and started on immunotherapy with Cemiplimab (Libtayo)...However, as our case shows, PD-1 inhibitor Cemiplimab (Libtayo) can be used with preserving allograft function on a Sirolimus-based immunosuppression regimen. More data is needed in to guide clinicians and to appropriately counsel patients regarding the risks and benefits of immunotherapy medications.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic Mfg.
    Recurrent Laryngeal Cancer with Uncommon Kidney Metastasis (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_2814;    
    Follow-up scans showed new metastatic lung disease treated with left upper lobe resection and cisplatin chemotherapy...He was recently started on ramipril for hypertension...The patient’s creatinine remained elevated at 2.5mg/dl with plan by head and neck oncology for combination carboplatin, taxol, and cetuximab given the rapidly progressive nature of the disease...It is important to recognize that kidney infiltration is also possible where treatment can be aimed at addressing the underlying malignancy. The above case is unique in that it highlights the rare entity of laryngeal carcinoma metastasizing to the kidneys and should be considered in patients presenting with kidney dysfunction and large kidneys.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Enrollment change, Trial completion date, Combination therapy, Metastases:  Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) -  Oct 11, 2019   
    P2,  N=108, Completed, 
    ClinicalTrials.gov identifier: NCT01836029. Active, not recruiting --> Completed | N=375 --> 108 | Trial completion date: Mar 2019 --> Jul 2019
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Triplet Succeeds in Colorectal Cancer. (Pubmed Central) -  Oct 9, 2019   
    A drug trio consisting of BRAF, MEK, and EGFR inhibitors may become the new standard of care in BRAF-mutant metastatic colorectal cancer. In the phase III BEACON CRC trial, encorafenib, binimetinib, and cetuximab significantly extended overall and progression-free survival and increased the objective response rate compared with cetuximab plus chemotherapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Metastases:  Cetuximab (ERBITUX (clinicaltrials.gov) -  Oct 9, 2019   
    P2,  N=110, Completed, 
    In the phase III BEACON CRC trial, encorafenib, binimetinib, and cetuximab significantly extended overall and progression-free survival and increased the objective response rate compared with cetuximab plus chemotherapy. Active, not recruiting --> Completed
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Diagnosing Meat Allergy After Tick Bite Without Delay. (Pubmed Central) -  Oct 9, 2019   
    In 2007, it was implicated as a cause of severe hypersensitivity reactions when a study found elevated levels of antibodies directed against this oligosaccharide among patients treated with cetuximab, a monoclonal antibody that contained an α -gal epitope...Here, we present a case of delayed urticarial angioedema due to a mammalian meat allergy caused by α-gal immunoglobulin E acquired after tick exposures, and the knowledge and patient education required to prevent recurrences. It is estimated that approximately 0.5% to 1.0% of the general population will experience an episode of angioedema in their lifetime, and this case demonstrates why clinicians in areas that are inhabited by ticks, particularly the Lone Star species, should include this cause in their differential.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Combination of chemotherapy and radiotherapy: A thirty years evolution. (Pubmed Central) -  Oct 8, 2019   
    The main example is the association of cetuximab and RT in head and neck carcinomas, even if, 14 years after the initial publication, the best way to use it is still unknown. New compounds as inhibitors of DNA-repair or immune checkpoints are under investigation and showed early promising results.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. (Pubmed Central) -  Oct 4, 2019   
    This study provides an extensive characterization of human glioma cell models, including stem-like models, with regard to ERBB receptor/ligand expression and signaling. Redundant signaling involving multiple ERBB family ligands and receptors may contribute to the challenges of developing more effective EGFR-targeted therapies for glioblastoma.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Rituxan (rituximab) / Roche, Biogen
    Deciphering the tumor-natural killer cell interactions to develop immunotherapies for lung adenocarcinoma () -  Oct 4, 2019 - Abstract #CRICIMTEATIAACR2019CRI-CIMT-EATI-AACR_188;    
    Decreased cytokine secretion and degranulation capabilities suggested that NK cells became less functional at later stages of the tumor development. As a therapeutic strategy to reinvigorate the NK cell function and to promote anti-tumor immunity, we are testing the in vivo efficacy of NK cell engagers, simultaneously targeting activating NK cell receptors and tumor cell surface antigens.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / Ono Pharma, BMS
    Plasma-derived exosomes in head and neck squamous cell carcinoma patients as potential biomarkers of response to immune therapies () -  Oct 4, 2019 - Abstract #CRICIMTEATIAACR2019CRI-CIMT-EATI-AACR_102;    
    P1
    To evaluate their role as biomarkers of response to immunotherapy, we monitored changes in the cargo of exosomes isolated from plasma of patients with head and neck squamous cell carcinoma (HNSCC) treated with Cetuximab, Ipilimumab and IMRT. Exosomes in plasma of cancer patients treated with immune therapies may serve as biomarkers of early response to Treatment.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Sustained compensatory p38 MAPK signaling activation following RAS/RAF/MEK inhibition induces upregulation of the immunosuppressive protein CD73 () -  Oct 4, 2019 - Abstract #CRICIMTEATIAACR2019CRI-CIMT-EATI-AACR_18;    
    Here we show that low CD73 expression significantly correlates with an improved response to cetuximab in colorectal cancer patients, thus highlighting the importance of CD73 in treatment targeting the MAPK pathway...Our results highlight the unfavorable effect of CD73 expression during treatment targeting the MAPK pathway and that compensatory signaling pathways is activated following MAPK inhibition, which might lead to increased CD73 expression in a subset of tumors. As a consequence, this might contribute to the development of immunologic resistance and emphasizes the importance of co-targeting CD73 in order to enhance the anti-tumor effect of MAPK targeting drugs.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, natural killer cell p46-related protein / Innate, AstraZeneca, Rituxan (rituximab) / Roche, Biogen
    Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_1132;    
    In vivo, they induced NK cell accumulation in tumors and promoted tumor clearance in preclinical mouse models of solid and invasive cancers. Our multispecific technology provides a versatile platform with many different format options and the potential to co-engage up to three activating receptors on NK cells and two different tumor antigens on cancer cells.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, NKTR-255 / Nektar Therapeutics
    NKTR-255, a polymer-conjugated IL-15 receptor agonist, enhances efficacy of therapeutic monoclonal antibodies with ADCC activity in solid tumor models (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_978;    
    NKTR-255 treatment of NK cells enhanced ADCC activity against tumor cells in vitro and in vivo efficacy of ADCC inducing antibodies in human solid tumor xenograft models. Furthermore, antibody single agent treatment resistant tumor models showed tumor growth inhibition in combination treatment with NKTR-255 suggesting potential for increasing response rates of therapeutic antibodies with ADCC mechanism of action.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Myeloid Cell-Selective STAT3 Inhibition Sensitizes Head and Neck Cancers to Radiation Therapy and Stimulates T-cell-Dependent Tumor Regression (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_870;    
    We recently found that combined modality therapy (CMT), using RT with concurrent cisplatin or cetuximab treatment, triggers potentially tolerogenic STAT3 signaling in circulating myeloid immune cells in patients with stage III-IV head and neck squamous cell carcinoma (HNSCC). Our clinical observations and animal study results suggest that myeloid cell-targeted inhibition of STAT3 together with CpG-mediated immunostimulation dramatically augment the outcome of radiation therapy against HPV-positive and HPV-negative HNSCC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic Mfg., Opdivo (nivolumab) / Ono Pharma, BMS
    Carboplatin and paclitaxel after anti-PD1 or anti-PDL1 therapy: A retrospective study in patients with squamous cell carcinoma of the head and neck (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_827;    
    Our preliminary data suggest that carboplatin and paclitaxel often induce objective responses in patients with prior treatment with anti-PD1/PD-L1 antibodies and that the clinical outcomes compare favorably to those seen in checkpoint inhibitor naive patients. If confirmed, these data suggest that there is no "opportunity cost" for administering immunotherapy in the first line.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Characterization of ADCC Resistance in Multiple Cancer Types (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_594;    
    Utilizing our in vitro model system of continuous selection pressure with NK92-CD16V effector cells and the mAbs Cetuximab and Trastuzumab we have generated three ADCC resistant cell lines from parental A431, SK-OV-3, and FaDu cells. Using multiple cell lines to model ADCC resistance has led to the discovery of a shared mechanism of resistance across cancer types that may reveal potential therapeutic targets for combination immunotherapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. (Pubmed Central) -  Oct 2, 2019   
    These results were found independently of the treatment received, and no beneficial effect of cetuximab on DFS or OS was observed in left-sided tumors. Although right-sided tumor location is associated with poor survival in patients with metastatic CC as previously reported, the association with disease recurrence appears to vary for patients with stage III CC and RAS or BRAF mutations vs those with double wild type.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
    Clinical, Journal:  Brief report: Afatinib and cetuximab in four patients with EGFR exon 20 insertion positive advanced non-small-cell lung cancer. (Pubmed Central) -  Oct 2, 2019   
    Although right-sided tumor location is associated with poor survival in patients with metastatic CC as previously reported, the association with disease recurrence appears to vary for patients with stage III CC and RAS or BRAF mutations vs those with double wild type. Dual EGFR blockade with afatinib and cetuximab may induce tumor responses in patients with EGFR exon 20 insertion positive NSCLC.
  • ||||||||||  napabucasin (BBI608) / Sumitomo Pharma
    Trial primary completion date, Metastases:  A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) -  Oct 2, 2019   
    P2,  N=203, Active, not recruiting, 
    Furthermore, it suggests a management of adverse drug reactions to improve the tolerability of the drug. Trial primary completion date: Jul 2019 --> Nov 2019